ClinicalTrials.gg
Sign In
CompletedNCT00664248Updated Apr 22, 2008

A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

A Phase 3 interventional study of IDP-110 and Clindamycin in Acne Vulgaris, sponsored by Dow Pharmaceutical Sciences. Completed at 35 sites in 3 countries. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-04-22.

Sponsored by Dow Pharmaceutical Sciences (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
1,414
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.

02

Conditions studied

  • Acne Vulgaris

Browse trials for

03

In context

Acne Vulgaris

790 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

This study's enrollment of 1,414 is above the median of 70 across 672 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Dow Pharmaceutical Sciences is the lead sponsor of 9 studies on the registry; none are open to participants now.

First submitted before Dow Pharmaceutical Sciences became part of Bausch Health Companies Inc..

Browse Dow Pharmaceutical Sciences studies →All Bausch Health Companies Inc. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of inflammatory and non-inflammatory lesions

Exclusion criteria

Exclusion Criteria:

  • Dermatological conditions of the face other than acne that could interfere with clinical evaluations
  • Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,414 participants (actual)

Study arms

  • Experimental
    1

    Drug: IDP-110

  • Active comparator
    2

    Drug: Clindamycin

  • Active comparator
    3

    Drug: Benzoyl peroxide

  • Placebo comparator
    4

    Drug: Vehicle

Interventions

  • DrugIDP-110

    Topical application for 12 weeks

  • DrugClindamycin

    Topical application for 12 weeks

  • DrugBenzoyl peroxide

    Topical application for 12 weeks

  • DrugVehicle

    Topical application for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in number of lesions

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in global severity

    Time frame: 12 weeks

07

Study locations

35 sites
  • Total Skin and Beauty Dermatology Center
    Birmingham, Alabama 35205, United States
  • University of Alabama, Birmingham
    Birmingham, Alabama 35233, United States
  • Medical Affiliated Research Center, Inc.
    Huntsville, Alabama 35801, United States
  • Dermatology Research of Arkansas
    Little Rock, Arkansas 72205, United States
  • Affiliated Research Institute - Dermatology
    San Diego, California 92108, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • University of California, San Diego, Pediatric and Adolescent Dermatology
    San Diego, California 92123, United States
  • Solano Clinical Research
    Vallejo, California 94589, United States
  • Dermatology Specialists, Inc.
    Vista, California 92083, United States
  • Clinical Research Specialists
    West Santa Monica, California 90404-2115, United States
  • Cherry Creek Dermatology Research Inc.
    Denver, Colorado 80246, United States
  • Longmont Medical Research Network
    Longmont, Colorado 80501, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • FXM Research
    Miami, Florida 33175, United States
  • Office of Scott Glazer, MD
    Buffalo Grove, Illinois 60089, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • The Nevada Center for Dermatology
    Reno, Nevada 89511, United States
  • Academic Dermatology
    Albuquerque, New Mexico 87106, United States
  • Triangle Medical Research Associates
    Cary, North Carolina 27511, United States
  • Unifour Medical Research Associates
    Hickory, North Carolina 28601, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • New Haven Medical Research
    Wilmington, North Carolina 28401, United States
  • Northwest Cutaneous Research Specialists
    Portland, Oregon 97210, United States
  • Oregon Medical Center, PC
    Portland, Oregon 97223, United States
  • Rivergate Dermatology
    Goodlettsville, Tennessee 37072, United States
  • Dermatology Associates
    Knoxville, Tennessee 37922, United States
  • Dermatology Research Associates
    Nashville, Tennessee 37203, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • The Center for Skin Research
    Houston, Texas 77056, United States
  • Progressive Clinical Research
    San Antonio, Texas 78229, United States
  • Dermatology Resarch Center
    Salt Lake City, Utah 84124, United States
  • Advanced Clinical Research - Jordan Valley
    West Jordan, Utah 84088, United States
  • Advanced Healthcare
    Milwaukee, Wisconsin 53209, United States
  • Dermatology and Skin Surgery Centre
    Belize City, Belize
  • Mediprobe Research
    New London, Ontario N5X 2P1, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006 and a primary completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2008
First posted
Apr 22, 2008
Start
Oct 2006
Primary completionActual
Aug 2007
Last update
Apr 22, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00664248
Lead sponsor
Dow Pharmaceutical Sciences
First posted
Apr 22, 2008
Start date
Oct 2006
Primary completion
Aug 2007
Last update
Apr 22, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acne Vulgaris →

Other studies from this sponsor

Dow Pharmaceutical Sciences →

Start the discussion